Newsroom 
TERUMO Japan | 中文 | Size Small Big
Terumo Granted CE Mark for Renal Sympathetic Denervation System

Terumo Granted CE Mark for Renal Sympathetic Denervation System

 



Tokyo ― Terumo Corporation (TSE: 4543 Section 1) announced CE marking for the commercial sale of the Iberis™ Renal Sympathetic Denervation System, which the company has consigned product development to Shanghai AngioCare Medical Technology Co., Ltd. (hereinafter "AngioCare") (Representative: Philip Wang), a Chinese company in renal sympathetic denervation technology for resistant hypertension treatment.
In December, 2012, Terumo formed a strategic alliance with AngioCare. Furthermore, the company has consigned product development to AngioCare and acquired the exclusive distribution rights for its renal sympathetic denervation technology on the global market.
Sales of Iberis in Europe will be commenced with its launch at the world’s leading cardiovascular intervention course, "EuroPCR" to be held in France in May, 2013.
Terumo aims to expand its renal sympathetic denervation business by launching Iberis in Asian and Latin American countries where the CE marked product is allowed for commercialization.


Renal sympathetic denervation

 



The renal sympathetic nerve plexus is a major contributor of hypertension. During renal sympathetic denervation, a catheter is introduced using standard interventional technique via the femoral artery, and is positioned in the renal artery under fluoroscopic guidance. The electrode at the distal tip of the catheter delivers high radio frequency through the wall of renal artery to ablate or disrupt the surrounding renal sympathetic nerves lying in the vessel. Renal sympathetic denervation using a catheter-based technique is highly expected to be a new, effective treatment option for the many patients with hypertension who do not respond to conventional drugs, or "resistant hypertension".